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Abstract In several studies on patients with bloodstream
infection (BSI), prior use of statins has been associated with
improved survival. Gram-positive and Gram-negative bacteria
alert the innate immune system in different ways. We, there-
fore, studied whether the relation between prior statin use and
90-day total mortality differed between Gram-positive and
Gram-negative BSI. We conducted a prospective observation-
al cohort study of 1,408 adults with BSI admitted to Levanger
Hospital between January 1, 2002, and December 31, 2011.
Data on the use of statins and other medications at admission,
comorbidities, functional status, treatment, and outcome were
obtained from the patients’ hospital records. The relation of
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statin use with 90-day mortality differed between Gram-
negative and Gram-positive BSI (p-value for interaction
0.01). Among patients with Gram-negative BSI, statin users
had significantly lower 90-day total mortality [odds ratio (OR)
0.42, 95 % confidence interval (CI) 0.23–0.75, p=0.003]. The
association remained essentially unchanged after adjusting for
the effect of sex, age, functional status before the infection,
and underlying diseases that were considered confounders
(adjusted OR 0.38, 95 % CI 0.20–0.72, p=0.003). A similar
analysis of patients with Gram-positive BSI showed no asso-
ciation of statin use with mortality (adjusted OR 1.22, 95% CI
0.69–2.17, p=0.49). The present study suggests that prior
statin use is associated with a lower 90-day total mortality in
Gram-negative BSI, but not in Gram-positive BSI.
Background
In spite of antibiotic and supportive therapy, bloodstream
infection (BSI) is still a major cause of mortality and morbid-
ity [1–3]. Measures to improve outcomes from BSI are nec-
essary. Several observational studies have assessed the rela-
tion between prior use of statins [3-hydroxy-3-methylglutaryl
coenzyme A (HMG CoA) reductase inhibitors] and the out-
come of BSI. The majority of the studies suggest that statin
use could have a beneficial effect in patients with BSI [4–8],
whereas some studies have shown no difference in mortality
between statin users and non-users [9–11].
Many former studies assessing the relation between statin
use and outcome of infection have not had verified BSI, nor
have they discriminated between Gram-positive and Gram-
negative etiology. As Gram-positive and Gram-negative bac-
teria alert the innate immune system in different ways [12, 13],
drugs that have anti-inflammatory properties may not have the
same effect in Gram-positive infection as they do in Gram-
negative infection. Only a few authors have attempted to study
this issue in patients [4, 7, 10, 11], and the results diverge. In
this prospective observational cohort study on BSI, we chose
to investigate the relation between prior statin use and 90-day
mortality in Gram-positive and Gram-negative BSI separately.
Materials and methods
Levanger Hospital serves a population of 87,000 as an emer-
gency facility in a defined geographical area. Since 1994, all
positive blood cultures at the hospital have been prospectively
recorded for surveillance purposes, and clinical information
has been recorded, in the following way: whenever a positive
blood culture was reported, a physician at the clinical ward
filled out a registration form. A team of three research nurses,
a subordinate doctor, and the main investigator reviewed the
patients’ records to verify the data and record additional
variables. Data on statin use were prospectively included in
the database from 2005, when we became aware of the early
studies on statin use and sepsis. Information on the use of
statins during the period 2002–2005 was recorded retrospec-
tively from hospital records. The present study includes BSIs
occurring between January 1, 2002 and December 31, 2011 in
patients ≥16 years of age. BACTEC 9240 (Becton Dickinson
Diagnostic Instrument Systems, Sparks, MD) was used for
blood culture testing [14]. If a blood culture was positive for
bacteria known to cause sepsis, only one positive vial was
required for inclusion in the present study. For common skin
contaminants (coagulase-negative staphylococci, alpha-
hemolytic streptococci, corynebacteria, etc.), at least two pos-
itive vials from separate venipunctures were required. An
episode of BSI was classified as polymicrobial if more than
one organism was isolated from one or more blood cultures
within a 72-h period.
For patients who had more than one episode with positive
blood culture in the 10-year period, only the first episode was
selected for this study. This cohort consisted of 1,408 patients.
BSI with Gram-negative or Gram-positive bacteremia accounted
for 1,356 episodes. The remaining cases consisted of eight
candidemias and 44 with mixed polymicrobial infection.
The exposure variable was prior statin use, defined as
taking a statin in the week before the time of positive blood
culture [15]. Two patients, whose statins were discontinued
more than one week before the date of the positive blood
culture, were categorized as non-statin users. We recorded
statin use and the specific statin and dosage from the patients’
hospital charts. The outcome variable was death from all
causes within 90 days after the first positive blood culture
[16]. The date of death was obtained from the patients’ elec-
tronic records, which is updated by the Civil Registration
System in Norway. The following variables were a priori
determined as possible confounders because they might be
associated with both statin use and mortality from BSI
(Table 1): age (<65 years, 65–79 years, ≥80 years); sex;
comorbidities; Charlson comorbidity index [17], categorized
as low (no underlying disease score), medium (score 1–2), or
high (score >2) [7]; nursing home resident (yes/no); functional
status (independent, partly independent, dependent, un-
known); immunosuppressive therapy; alcohol abuse; smoking
(no smoking, former smoker, present smoker); focus of infec-
tion (urinary tract, lungs, biliary tract, gastrointestinal tract,
other, unknown); use of antibiotics before admission; and
place of acquisition (community, healthcare, hospital).Wheth-
er the current BSI episode was nosocomial, healthcare-asso-
ciated, or community-acquired was determined according to
commonly used definitions [18, 19].
Variables expressing the severity of the current BSI (sys-
temic inflammatory response syndrome, organ failure, hypo-
tension, hypoperfusion, sepsis, severe sepsis, and septic shock
[20]), severe organ failure (defined as SOFA score >2 in any
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Table 1 Baseline characteristics of 1,356 adult patients with Gram-negative or Gram-positive bloodstream infection (BSI) by statin use at Levanger
Hospital, Norway, 2002–2011
Variable Gram-negative BSI (n=784) Gram-positive BSI (n=572)
No statin use
(n=646)
Statin use
(n=138)
p-Value No statin use
(n=474)
Statin use
(n=98)
p-Value
Age <0.001 0.021
<65 years 185 (28.6) 25 (18.1) 159 (33.5) 26 (26.5)
65–79 years 189 (29.3) 71 (51.4) 153 (32.3) 45 (45.9)
≥80 years 272 (42.1) 42 (30.4) 162 (34.2) 27 (27.6)
Female sex 367 (56.8) 67 (48.6) 0.060 196 (41.4) 35 (35.7) 0.29
Chronic renal insufficiency 52 (8.0) 16 (11.6) 0.17 36 (7.6) 19 (19.4) <0.001
Malignancy
Solid tumor 148 (22.9) 32 (23.2) 0.94 99 (20.9) 21 (21.4) 0.93
Hematological cancer 35 (5.4) 3 (2.2) 0.11 38 (8.0) 3 (3.1) 0.085
Diabetes mellitus 87 (13.5) 41 (29.7) <0.001 70 (14.8) 35 (35.7) <0.001
Hypertension 186 (28.8) 77 (55.8) <0.001 127 (26.8) 40 (40.8) 0.003
Cardiovascular disease 212 (32.8) 91 (65.9) <0.001 153 (32.3) 67 (68.4) <0.001
Coronary heart disease 118 (18.3) 65 (47.1) <0.001 88 (18.6) 50 (51.0) <0.001
Congestive heart failure 59 (9.1) 16 (11.6) 0.36 49 (10.3) 14 (14.3) 0.25
Peripheral vascular disease 35 (5.4) 15 (10.9) 0.016 30 (6.3) 18 (18.4) <0.001
Cerebral vascular disease 77 (11.9) 32 (23.2) <0.001 52 (11.0) 18 (18.4) 0.041
Chronic liver disease 10 (1.5) 1 (0.7) 0.54 14 (3.0) 1 (1.0) 0.31
Chronic pulmonary disease 94 (14.6) 24 (17.4) 0.41 78 (16.5) 16 (16.3) 0.99
Rheumatological/immunological disease 55 (8.5) 13 (9.4) 0.72 44 (9.3) 11 (11.2) 0.56
Charlson comorbidity index 0.014 <0.001
Low (0) 187 (28.9) 23 (16.7) 144 (30.4) 10 (10.2)
Medium (1–2) 278 (43.0) 69 (50.0) 209 (44.1) 43 (43.9)
High (>2) 181 (28.0) 46 (33.3) 121 (25.5) 45 (45.9)
Nursing home resident 85 (13.2) 8 (5.8) 0.021 47 (9.9) 2 (2.0) 0.017
Functional status prior to the present BSI 0.050* 0.035*
Independent 365 (56.5) 87 (63.0) 307 (64.8) 70 (71.4)
Partly independent 178 (27.6) 38 (27.5) 108 (22.8) 26 (26.5)
Dependent 97 (15.0) 11 (8.0) 52 (11.0) 2 (2.1)
Unknown 6 (0.9) 2 (1.4) 7 (1.5) 0
Immunosuppressive therapy 86 (13.3) 19 (13.8) 0.79 62 (13.1) 13 (13.3) 0.93
Alcohol abuse 30 (4.6) 4 (2.9) 0.45 20 (4.2) 2 (2.0) 0.38
Smoking
Non-smoker 416 (64.4) 74 (53.6) 0.017 278 (58.6) 49 (50.0) 0.14
Former smoker 110 (17.0) 38 (27.5) 0.004 105 (22.2) 33 (33.7) 0.026
Present smoker 120 (18.6) 26 (18.8) 0.92 91 (19.2) 16 (16.3) 0.65
Focus of infection
Urinary tract 358 (55.4) 76 (55.1) 0.98 45 (9.5) 10 (10.2) 0.83
Lungs 46 (7.1) 5 (3.6) 0.15 164 (34.6) 31 (31.6) 0.67
Biliary tract 95 (14.7) 26 (18.8) 0.21 14 (3.0) 5 (5.1) 0.32
Gastrointestinal tract 49 (7.6) 8 (5.8) 0.38 11 (2.3) 2 (2.0) 0.81
Skin or soft tissue 17 (2.6) 2 (1.4) 0.45 66 (13.9) 13 (13.3) 0.71
Other 25 (3.9) 4 (2.9) 0.69 105 (22.2) 28 (28.6) 0.16
Unknown 56 (8.7) 17 (12.3) 0.17 69 (14.6) 9 (9.2) 0.16
Systemic antibiotic therapy before admission 93 (14.4) 20 (14.5) 0.99 49 (10.3) 4 (4.1) 0.076
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organ [15, 21]), and admission to an intensive care unit (ICU)
were recorded, but not considered confounders. Instead, they
may bemediators in the pathway between prior statin use and
mortality and, therefore, should not be adjusted for in the
analyses [7, 22, 23].
Appropriate initial antibiotic therapy was defined as cor-
rectly dosed intravenous antibiotic therapy given within 24 h
of the time that the blood culture specimen was obtained, with
a regimen that was active in vitro against the microbe(s)
isolated from blood culture(s) [24]. This variable was not
adjusted for in the main analyses, as it was not considered a
confounder. Appropriate initial antibiotic therapy is, indeed,
strongly associated with outcome of BSI, but it is not associ-
ated with prior statin use in such a way that it influences
whether a person has been prescribed statin medication. Prior
statin use may be associated with the initial antibiotic therapy
if statin use mitigates the inflammatory response so that
symptoms are masked and, therefore, appropriate initial anti-
biotic therapy, is delayed. In this case, appropriate initial
antibiotic therapy is a mediator in the pathway between statin
use and death, and not a confounder. On the other hand, one
might postulate some unknown variable that influences
whether people are prescribed statin medication and also
influences whether they receive appropriate initial antibiotic
therapy (e.g., some underlying condition that is not included
in the Charlson comorbidity index). To reduce the influence of
such an unknown confounder, we also performed an analysis
including adjustment for appropriate initial antibiotic therapy.
Ethics
TheRegional Committee for Ethics inMedical Research,Health
Region IV, Norway approved the study. The Ethics Committee
waived the need for informed consent because this was an
observational study, the treatment of the patients was standard,
and no samples were taken for the purposes of the research.
Statistical analyses
Proportions were compared using the unconditional z-pooled
test, which is the unconditional version of the Pearson Chi-
squared test [25]. Unordered r × c tables were analyzed using
the exact version of the Pearson Chi-squared test. The exact
Cochran–Armitage test was used to test for trends in proportions.
Univariable analysis of mortality curves was done with Kaplan–
Meier analysis. The relation between prior statin use and 90-day
total mortality was analyzed using logistic regression. Estimates
were accompanied by 95 % confidence intervals (CIs).
Two-sided p-values<0.05 were considered significant. Statistical
analyses were performed with SPSS 18 and StatXact 9.
Results
During the 10-year period, 784 patients with Gram-negative
BSI and 572 with Gram-positive BSI were identified. 17.6 %
of those with Gram-negative and 17.1 % of those with Gram-
positive BSI were statin users. The patient characteristics are
shown in Table 1. In both Gram-negative and Gram-positive
BSI, statin users had a higher burden of comorbid diseases,
such as diabetes, hypertension, and cardiovascular disease,
and they also had a higher Charlson comorbidity index. Var-
iables expressing the severity of infection at the time of
diagnosis were not significantly different in statin users and
non-users. In Gram-positive BSI, the proportion of patients
admitted to an ICU was higher in statin users.
Table 1 (continued)
Variable Gram-negative BSI (n=784) Gram-positive BSI (n=572)
No statin use
(n=646)
Statin use
(n=138)
p-Value No statin use
(n=474)
Statin use
(n=98)
p-Value
Place of acquisition
Community-acquired 335 (51.9) 76 (55.1) 0.52 262 (55.3) 49 (50.0) 0.44
Acquired in hospital 76 (11.8) 21 (15.2) 0.28 73 (15.4) 16 (16.3) 0.81
Healthcare-associated 235 (36.4) 41 (29.7) 0.15 139 (29.3) 33 (33.7) 0.51
Variables expressing the severity of infection
Severe sepsis or septic shock at the time of diagnosis 149 (23.1) 25 (18.1) 0.22 95 (20.0) 25 (25.5) 0.22
Severe organ failure (SOFA score >2 in any organ) at
the time of diagnosis
90 (13.9) 19 (13.8) >0.99 75 (15.8) 21 (21.4) 0.18
Stay in intensive care unit (ICU) 117 (18.1) 26 (18.8) 0.81 107 (22.6) 36 (36.7) 0.005
Appropriate initial antibiotic therapy 548 (84.8) 122 (88.4) 0.35 397 (83.8) 88 (89.8) 0.16
Data are presented as number of patients (%)
*Excluding unknowns
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The distribution of the microbial agents in relation to statin
use is shown in Table 2. The distribution of microbes was
essentially similar among statin users and non-users, except
that Klebsiella spp. were more common among statin users
and that some Gram-negative microbes (Haemophilus
influenzae, Neisseria meningitidis and “Other aerobic Gram-
negative organisms”) did not occur in statin users.
Figure 1 shows the mortality curves for patients with
Gram-negative and Gram-positive BSI. In Gram-negative
BSI, the total 90-day mortality was 10.1 % (14/138) in statin
users and 21.4 % (138/645) in non-statin users, p=0.002. In
Gram-positive BSI, the total 90-daymortality was 28.6% (28/
98) in statin users and 27.0 % (128/474) in non-statin users,
p=0.90.
The results of logistic regression analysis of the relation
between statin use and 90-day total mortality are shown in
Table 3. For the total BSI cohort, we found a negative asso-
ciation between prior statin use and 90-day mortality [odds
ratio (OR) 0.69, 95 % CI 0.49–0.98, p=0.040). The associa-
tionwas not mitigated by adjustment for possible confounding
factors. Among patients with Gram-negative BSI, the mortal-
ity was significantly lower in statin users (OR 0.42, 95 % CI
0.23–0.75, p=0.003). In Gram-positive BSI, there was no
association between statin use and mortality. Adjustment for
variables considered confounders did not weaken the associ-
ation between statin use and 90-day mortality in Gram-
Table 2 Microbial agents in 784 episodes of Gram-negative BSI and 572 episodes of Gram-positive BSI, total and by statin use
Microbial agent(s) No statin Statin Total p-Value
Gram-negative microorganisms
Escherichia coli 400 (61.9) 95 (68.8) 495 (63.1) 0.13
Klebsiella spp. 54 (8.4) 20 (14.5) 74 (9.4) 0.025
Proteus spp. 29 (4.5) 3 (2.2) 32 (4.1) 0.21
Enterobacter spp. 20 (3.1) 3 (2.2) 23 (2.9) 0.69
Other Enterobacteriaceae 19 (2.9) 6 (4.3) 25 (3.2) 0.44
Pseudomonas spp. 35 (5.4) 5 (3.6) 40 (5.1) 0.44
Haemophilus influenzae 15 (2.3) 0 15 (1.9) 0.079
Neisseria meningitidis 8 (1.2) 0 8 (1.0) 0.20
Other aerobic Gram-negative organisms 10 (1.5) 0 10 (1.3) 0.14
Anaerobic Gram-negative rods 28 (4.3) 5 (3.6) 33 (4.2) 0.88
Mixed Gram-negative aerobic or anaerobic rods 28 (4.3) 1 (0.7) 29 (3.7) 0.079
Total Gram-negative microorganisms 646 (100) 138 (100) 784 (100)
Gram-positive microorganisms
Streptococcus pneumoniae 162 (34.2) 27 (27.6) 189 (33.0) 0.23
Staphylococcus aureus 120 (25.3) 32 (32.7) 152 (26.6) 0.12
Beta-hemolytic streptococci 70 (14.8) 13 (13.3) 83 (14.5) 0.74
Enterococcus spp. 42 (8.9) 10 (10.2) 52 (9.1) 0.66
Viridans group streptococci 33 (7.0) 7 (7.1) 40 (7.0) 0.94
Coagulase-negative staphylococci 33 (7.0) 6 (6.1) 39 (6.8) 0.88
Listeria monocytogenes 3 (0.6) 1 (1.0) 4 (0.7) 0.88
Anaerobic Gram-positive microorganisms 6 (1.3) 1 (1.0) 7 (1.2) 0.89
Mixed Gram-positive aerobic or anaerobic BSI 5 (1.1) 1 (1.0) 6 (1.0) 0.68
Total Gram-positive microorganisms 474 (100) 98 (100) 572 (100)
Data are presented as number of patients (%)
Gram-positive, non-statin user
Gram-positive, statin user
Gram-negative, non-statin user
Gram-negative, statin user
Fig. 1 Mortality curves for patients with Gram-negative and Gram-
positive bloodstream infection (BSI) stratified by statin use
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negative BSI (adjusted OR 0.38, 95 % CI 0.20–0.72, p=
0.003). The relations between prior statin use and 90-day
mortality in Gram-negative and Gram-positive BSI were sig-
nificantly different; the adjusted OR for the interaction term
was 2.95 (95 % CI 1.26–6.89, p=0.012).
In an analysis including adjustment for appropriate initial
antibiotic therapy, the effect estimates did not change (adjust-
ed OR 0.38, 95 % CI 0.20–0.73, p=0.004 and OR 1.21, 95 %
CI 0.68–2.14, p=0.52 for Gram-negative and Gram-positive
BSI, respectively).
Adjusted ORs for the relation between statin use and 90-
day mortality were similar when disease categories (e.g.,
diabetes, cardiovascular disease) were used instead of the
Charlson comorbidity index for the total cohort (OR 0.62,
95 % CI 0.41–0.94, p=0.026), Gram-negative BSI (OR
0.37, 95 % CI 0.18–0.74, p=0.005), and Gram-positive BSI
(OR 1.13, 95 % CI 0.62–2.07).
After excluding bacterial subgroups with zero statin users
(n=33), the association between statin use and 90-day mor-
tality in Gram-negative BSI did not change, either unadjusted
(OR 0.44, 95 % CI 0.24–0.78, p=0.006) or after adjustment
for confounders (OR 0.41, 95 % CI 0.21–0.78, p=0.007).
For some variables included in the main analysis
(focus of infection, use of antibiotics before admission,
and place of acquisition), the association with prior
statin use is unclear, and it is uncertain whether these
variables fulfil the criteria for being a confounder. Ad-
ditionally, we repeated the analysis after excluding these
variables from the model, but the relations between
prior statin use and 90-day mortality in Gram-negative
(OR 0.37, 95 % CI 0.20–0.70, p=0.002) and Gram-
positive BSI (OR 1.00, 95 % CI 0.58–1.75) remained
unchanged.
Discussion
In this cohort study of patients with BSI, prior statin use was
associated with reduced 90-day mortality in Gram-negative,
but not in Gram-positive, BSI. To our best knowledge, no
previous research has reported this finding. The effect mea-
sures were not changed by adjustment for variables that were
considered confounding factors.
In the total cohort of BSI, the unadjusted OR for mortality
among statin users compared with non-users did not differ
much from what has been found by other investigators [7, 9,
11]. In one study, adjustment for possible confounding factors
attenuated the effect measure to a value above 1 [11]. A
population-based prospective cohort study on statin use and
community-acquired pneumonia [26] raised concerns that
previous studies indicating benefits of statins in patients with
sepsis had been measuring and reporting a healthy user effect.
In that study, statin users were less likely to die or to be
admitted to an ICU. After adjusting for confounding factors
that reflect patient frailty or healthy user behavior, no reduc-
tion in either mortality or the need for admission to an ICU in
statin users was found.
In the present study, a significantly lower proportion
of statin users were functionally dependent patients or
nursing home residents compared with non-users. The
proportion of former smokers was significantly higher
among statin users. However, these associations of statin
use were essentially similar in Gram-negative and Gram-
positive BSI. Therefore, it seems unlikely that the ob-
served difference in the possible preventive effect of
statins between Gram-negative BSI and Gram-positive
BSI in our study could be explained by a healthy user
effect.
Table 3 Logistic regression analysis of the relation between prior statin use and 90-day total mortality
No. of deaths/patients (%) Unadjusted OR
(95 % CI)
p-Value Adjusted* OR
(95 % CI)
p-Value
Any BSI
No statin 285/1,164 (24.5) 1 (reference) 1 (reference)
Statin 45/245 (18.4) 0.69 (0.49–0.98) 0.040 0.63 (0.43–0.95) 0.025
Gram-negative BSI
No statin 138/646 (21.4) 1 (reference) 1 (reference)
Statin 14/138 (10.1) 0.42 (0.23–0.75) 0.003 0.38 (0.20–0.72) 0.003
Gram-positive BSI
No statin 128/474 (27.0) 1 (reference) 1 (reference)
Statin 28/98 (28.6) 1.08 (0.67–1.75) 0.75 1.22 (0.69–2.17) 0.49
*Adjusted for age (<65 years, 65–79 years, ≥80 years); sex; Charlson comorbidity index; nursing home resident; functional status (independent, partly
independent, dependent, unknown); immunosuppressive therapy; alcohol abuse; smoking (no smoking, former smoker, present smoker); focus of
infection (urinary tract, lungs, biliary tract, gastrointestinal tract, other, unknown); use of antibiotics before admission; and place of acquisition
(community, healthcare, hospital)
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Most previous investigators have dealt with infection,
sepsis, or BSI as if these categories represent homogenous
groups with regard to pathogenesis or assumed preventive
effect of statins. A few articles reported some data on the
relations between statin use and death in Gram-positive
and Gram-negative BSI separately. Liappis et al. [4] re-
ported trends of reduced mortality rates in statin users
with Gram-negative infection (1/19 vs. 48/223, p=0.13)
or Staphylococcus aureus infection (0/15 vs. 22/130, p=
0.13). Yang et al. [10] found a trend of lower mortality in
statin users with Gram-negative bacteremia (10.3 % vs.
16.4 %, p=0.25), but not in Gram-positive bacteremia
(33.3 % vs. 27.8 %, p=0.50). Thomsen et al. [7] did not
find such a trend in the enterobacterial group of Gram-
negative bacteria (adjusted 30-day mortality rate ratio
1.07, 95 % CI 0.61–1.86, p=0.82), nor did Leung et al.
find a negative association between statin use and death in
Gram-negative BSI (adjusted hazard ratio 1.10, 95 % CI
0.87–1.39) [11]. However, the latter had adjusted for
variables expressing the severity of the current infection,
i.e., factors that should be considered as mediators rather
than confounders, and such an adjustment may attenuate
the true associations [22]. Recently, López-Cortés et al.
found a negative association between statin use and death
within 14 days from Staphylococcus aureus BSI (adjusted
OR 0.08, 95 % CI 0.01–0.66, p=0.02) [8].
Statins are renowned for their anti-inflammatory and
pleiotropic lipid-lowering independent effects. They exert
their anti-inflammatory effects through their implication
on a variety of molecular pathways of the innate and
adaptive immune system, such as their impact on the
circulating levels of inflammatory cytokines, as well as
anti-coagulant and anti-proliferative effects [27, 28].
With regards to sepsis, many in vitro and animal studies
have demonstrated that statins attenuate endotoxin-
induced inflammatory responses [29]. Similarly, statins
have been found to diminish inflammatory responses
induced by Staphylococcus aureus lipoteichoic acid
[30]. However, there are few studies that have explored
the mechanisms for differential effects of statins in
Gram-positive and Gram-negative BSI, as observed in
the present study. Gram-positive and Gram-negative bac-
teria have different cell wall components and may stim-
ulate different toll-like receptors (TLRs) on cells of the
innate immune system, initiating the transcription of
different inflammatory mediator genes. Interestingly,
there are several studies showing that statins decrease
lipopolysaccharide (LPS) signaling through the downreg-
ulation of TLR4 expression on monocytes [31]. Although
some studies suggest that statins may also suppress
TLR2 signaling in Gram-positive infection, statins may
not inhibit the lipoprotein-induced pathway via TLR2
and the LPS-induced pathway via TLR4 to the same
extent [32]. Indeed, there are some studies showing that
statins inhibit TLR4-mediated activation of interferon
regulatory factor 3 (IRF3) and interferon-beta production
in macrophages stimulated by LPS, while no such effects
were observed for TLR2 stimulation [33]. The clinical
relevance of these findings is, however, unknown and
require further examination. Nevertheless, they illustrate
that there may be molecular mechanisms supporting the
findings of different effects of statins in Gram-positive
and Gram-negative BSI.
Our findings indicate that the possible preventive ef-
fect of statins in BSI may be a subgroup effect seen in
Gram-negative, but not in Gram-positive, infection.
Whether a negative association between statin use and
mortality in Gram-negative BSI really exists as a biolog-
ical interaction should be further investigated, preferably
by randomized controlled studies (RCTs). As of yet, few
RCTs have been performed [34, 35], and though several
are presently in progress [36], they are designed to study
the effect of statin treatment in ongoing infection, not the
prophylactic effect of statin use prior to infections. One
RCT has shown improved survival in atorvastatin-treated
ICU patients with severe sepsis if they had been prior
statin users, but no effect was found in patients who
received de novo statin therapy [35]. RCTs, so far, have
not assessed whether different etiologic agents influence
the relation between prior statin use and the outcome of
infections.
Strengths and weaknesses of the study
The strength of our study is that our bacteremia database
contains confirmed diagnoses and variables collected
from the patients’ hospital data, which include medical
records. Thus, we have more reliable data than diagnos-
tic information from only discharge databases. Our co-
hort has a sufficient number of patients in the different
groups, which makes it possible to assess the relation
between statin use and 90-day mortality, an important
endpoint in prior studies.
The study has the weakness of being an observational
study, burdened with the risk of confounding. Socioeco-
nomic factors have not been adjusted for, but severe
confounding by socioeconomic differences seems unlike-
ly because statin prescriptions are reimbursed, and access
to hospital treatment is the same for all citizens in
Norway. In addition, we have not adjusted for vaccina-
tions, e.g., pneumococcus vaccine or influenza vaccine,
which some previous authors have regarded as “healthy
user” markers. Nonetheless, we are not aware of con-
founders that would be likely to cause a strong associa-
tion of statin use with reduced mortality in Gram-nega-
tive, but not in Gram-positive, BSI.
Eur J Clin Microbiol Infect Dis
Conclusion
In the present study, the relation between statin use and 90-day
total mortality was different in Gram-positive and Gram-
negative bloodstream infection (BSI). In Gram-negative BSI,
statin use was associated with lower 90-day mortality, which
was not the case in Gram-positive BSI.
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